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Fecal Calprotectin Correlates More Closely With the Simple
Endoscopic Score for Crohn's Disease (SES-CD) than CRP,
Blood Leukocytes, and the CDAI
Abstract
OBJECTIVES:Studies evaluating the correlation between the widely used Simple Endoscopic Score for
Crohn's disease (SES-CD) and noninvasive markers are scarce. The aim of this study was to evaluate the
correlation between the SES-CD and fecal calprotectin, C-reactive protein (CRP), blood leukocytes, and
the Crohn's disease activity index (CDAI).METHODS:Crohn's disease patients undergoing complete
ileocolonoscopy were prospectively enrolled and scored independently according to the SES-CD and the
CDAI. SES-CD was defined as follows: inactive 0-3; mild 4-10; moderate 11-19; and high
>/=20.RESULTS:Values in CD patients (n=140 ileocolonoscopies) compared with controls (n=43) are
as follows: calprotectin, 334+/-322 vs. 18+/-5 mug/g; CRP, 26+/-29 vs. 3+/-2 mg/l; and blood
leukocytes, 9.1+/-3.4 vs. 5.4+/-1.9 g/l (all P<0.001). The SES-CD correlated closest with calprotectin
(Spearman's rank correlation coefficient r=0.75), followed by CRP (r=0.53), blood leukocytes (r=0.42),
and the CDAI (r=0.38). Calprotectin was the only marker that could discriminate inactive endoscopic
disease from mild activity (104+/-138 vs. 231+/-244 mug/g, P<0.001), mild from moderate activity
(231+/-244 vs. 395+/-256 mug/g, P=0.008), and moderate from high activity (395+/-256 vs. 718+/-320
mug/g, P<0.001). The overall accuracy for the detection of endoscopically active disease was 87% for
calprotectin (cutoff 70 mug/g), 66% for elevated CRP, 54% for blood leukocytosis, and 40% for the
CDAI >/=150.CONCLUSIONS:Fecal calprotectin correlated closest with SES-CD, followed by CRP,
blood leukocytes, and the CDAI. Furthermore, fecal calprotectin was the only marker that reliably
discriminated inactive from mild, moderate, and highly active disease, which underlines its usefulness
for activity monitoring.
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Abstract  
Background: Studies evaluating the correlation between the widely used simple endoscopic 
score for Crohn’s disease (SES-CD) and non-invasive markers are scarce. Aim: To evaluate 
the correlation between a semi-quantitative SES-CD and fecal calprotectin, Crohn’s disease 
activity index (CDAI), C-reactive protein (CRP) and blood leukocytes.  
Methods: CD patients undergoing complete ileo-colonoscopy were prospectively enrolled 
and scored independently according the SES-CD and CDAI. SES-CD was defined as 
follows: inactive 0-3; mild 4-10; moderate 11-19; high ≥20.  
Results: Values in CD patients (n=140) compared to controls (n=43): Calprotectin: 334322 
vs. 185g/g, CRP 2629 vs. 32mg/L, blood leukocytes 9.13.4 vs. 5.41.9G/L (all P < 
0.001). The SES-CD correlated closest with calprotectin (Spearman’s rank correlation 
coefficient r = 0.75), followed by CRP (r = 0.53), blood leukocytes (r = 0.42), and CDAI (r = 
0.38). Calprotectin was the only marker that could discriminate inactive endoscopic disease 
from mild activity (104138 vs. 231244g/g, P <0.001), mild from moderate activity 
(231244 vs. 395256g/g, P =0.008), and moderate from high activity (395256g/g vs. 
718320g/g, P <0.001). The overall accuracy for the detection of endoscopically active 
disease was 84% for calprotectin, 66% for elevated CRP, and 54% for blood leukocytosis, 
and 40% for CDAI ≥150. 
Conclusions: Fecal calprotectin correlated closest with SES-CD, followed by CRP, CDAI, and 
blood leukocytes. Furthermore, fecal calprotectin was the only marker that reliably 
discriminated inactive from mild, moderate, and highly active disease which underlines its 
usefulness for activity monitoring.  
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INTRODUCTION 
The assessment of Crohn’s disease (CD) activity is based on a combination of symptoms, 
clinical findings, and endoscopy. However, there is often an insufficient correlation between 
these diagnostic elements.1,2,3,4,5,6 Although considered the gold standard method for 
assessment of intestinal inflammation, ileo-colonoscopy has the disadvantage of being 
invasive, time-consuming, expensive, and sometimes uncomfortable for patients.  
To overcome these limitations, several laboratory markers have been evaluated regarding 
their performance for monitoring Crohn’s disease activity. Active inflammation in CD patients 
is associated with an acute phase reaction and migration of leukocytes to the gut. Thereby, 
various proteins can be measured in serum and feces.7 C-reactive protein (CRP), produced 
by hepatocytes upon the stimulation by proinflammatory cytokines such as interleukins 1 and 
6, has been found to be associated with clinical and endoscopic activity in IBD.8,9,10 Fecal 
calprotectin represents 60% of cytosolic proteins in granulocytes. The amount of calprotectin 
in feces is therefore proportional to the neutrophil migration to the gastrointestinal mucosa. 
Fecal calprotectin is stable against degradation for up to one week at room temperature.11 It 
accurately distinguishes inflammatory bowel disease (IBD) from non-inflammatory bowel 
diseases such as irritable bowel syndrome.12 Several publications in pediatric and adult 
cohorts have demonstrated a correlation of the amount of fecal calprotectin with the severity 
of mucosal inflammation.13,14,15 A good correlation between fecal calprotectin and the 
Crohn’s Disease Index of Severity (CDEIS) has already been demonstrated.16,17 However, 
the CDEIS is demanding to complete and time-consuming in clinical practice. Therefore, the 
simple endoscopic score for Crohn’s disease (SES-CD) was developed and validated in 
2004.18 This score has a good correlation with the CDEIS, but is much easier to perform and 
therefore more frequently used in clinical practice. So far, data regarding the correlation of 
fecal calprotectin with SES-CD are scarce, and there is especially a paucity of studies 
evaluating the endoscopic disease activity with calprotectin in relation to other 
biomarkers.19,20 Knowledge about the test performance of different biomarkers to 
discriminate classes of inflammatory activity is important for the early detection of relapses 
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and for tailoring the individual therapy. This appraisal is supported by recently published 
papers claiming that the optimal therapeutic target to modify disease course in IBD patients 
should not only be clinical remission, but also mucosal healing as this item has shown an 
association with reduced need for surgery and hospitalization in CD patients.21,22   
We hypothesized, that fecal calprotectin would be superior to CDAI, CRP, and blood 
leukocytes to discriminate the endosopic disease activity.  
Thus, we aimed to answer the following questions in this study: first, is there any non-
invasive marker able to discriminate between inactive, mild, moderate and severe 
endoscopic activity? And second, what is the overall test accuracy of the CDAI and the 
various biomarkers for detection of endoscopically active disease?  
 
 
METHODS 
Participants 
Of 170 adult outpatients and inpatients with previously confirmed diagnosis of ulcerative 
colitis referred for colonoscopy to the Departments of Gastroenterology of the University 
Hospitals Bern and Basel between March 2006 and June 2008, 122 patients were included 
(72%). They were diagnosed on the basis of standard clinical, endoscopic, and histologic 
criteria.23 The study was conducted with approval of the local ethics committees. Patients 
were first instructed by the local investigator, then they were provided with a fecal specimen 
collection set consisting of 2 fecal tubes (1 tube for 1ml, order number 55478, Sarstedt AG, 
Nümbrecht Germany, and one tube for stool culture and Cl. difficile toxin assay). Collection 
of the fecal specimens was performed by the patients themselves. The fecal specimens from 
the outpatients were shipped by mail to the laboratory. In inpatients, the fecal collection set 
was prepared by a trained nurse and then sent to the laboratory. The fecal samples for 
bacterial analysis were processed immediately after receipt whereas fecal samples for 
calprotectin were stored at -40C until analysis. Blood samples for measurement of a full 
blood count and CRP were delivered by the patients within 3 days prior to endoscopy. Ten of 
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the included CD patients (8%) underwent an upper endoscopy (due to upper abdominal 
complaints) at the same day when ileo-colonoscopy was performed, no CD-related lesions or 
reflux-associated lesions could be detected in this subgroup.  
Inclusion criteria: Disease duration > 3 months, complete ileocolonoscopy including biopsies 
(at least 2 biopsies from terminal ileum and 4 colonic biopsies from affected regions), age 18-
85 years, fecal samples delivered from 3 to 1 days before ileocolonoscopy (bowel 
preparation was not started until the fecal specimen was delivered).  
Exclusion criteria: Incomplete ileocolonoscopy (cecum not reached), infectious entero-colitis 
(positive stool culture for Salmonella, Shigella, Campylobacter, positive Cl. difficile Toxin A+B 
assay, cytomegalovirus positive in conventional histology or in immunohistochemistry), 
colorectal cancer, ulcerative colitis, indeterminate colitis, urinary incontinence (risk of 
contamination of fecal samples), inability to collect fecal samples, pregnancy, history of 
extensive bowel resection (ileosigmoidostomy, ileorectostomy), ostomy, symptoms related 
mainly to perianal fistulizing disease, known Crohn’s disease of esophagus or stomach or 
duodenum, regular intake of aspirin and/or NSAID ( 2 tablets/week). Of a total of 173 
screened CD patients, 51 were excluded: 8 because of incomplete ileocolonoscopy 
(strictures that could not be passed after balloon dilation), 3 for not delivering fecal samples 
on time, 3 for known and active CD of upper gastrointestinal tract, one for intake of NSAID, 
one for positive Clostridium difficile toxin assay, and 35 for not being willing to participate in 
the study. 
 
Endoscopic disease activity 
During the study period, 18 patients underwent ileocolonoscopy twice, therefore 140 
endoscopies were performed in 122 patients. Indications for endoscopy were clinically active 
disease (flare) (n=76, 54%), assessment of endoscopic activity after medical treatment 
(n=45, 32%), dysplasia surveillance for long-standing disease (n=15, 11%), and stricture 
dilation (n=4, 3%). Five  experienced board certified gastroenterologists (AMS, CB, AS, SV, 
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FS), every of them with at least 5 years of experience in performing ileocolonoscopy, 
performed the endoscopies and graded the findings according to the SES-CD.  
For calculating the SES-CD, the intestine was divided into five segments: ileum, right colon, 
transverse colon, left colon, and rectum. The degree of disease involvement in each of the 
five segments was determined by the assessment of four parameters: presence and size of 
ulcers (score 0-3), extent of ulcerated surface (score 0-3), extent of affected surface (score 
0-3), and presence and type of narrowing (score 0-3).18daperno  The sum of the score for each 
endoscopic variable ranges from 0 to 15, except for stenosis, where it varies between 0 and 
11, because 3 represents a stenosis through which a colonoscope cannot be passed, and 
therefore can be observed only once. The lowest possible SES-CD was 0, representing an 
intestine without any lesions; the highest possible score was 56 points. The clinical disease 
activity was assessed by measurement of the CDAI by a physician not performing the 
colonoscopy.4 All gastroenterologists performing the endoscopies were unaware of the 
results of the CDAI, fecal calprotectin, CRP, and blood leukocytes to avoid bias.  
The controls were healthy persons from the clinical and laboratory staff willing to provide 
blood and fecal samples. All healthy controls were free of symptoms and had no history of 
abdominal complaints. The control group did not undergo endoscopy. Except for birth control 
pills in some women, these persons were not on any regular medication.  
So far there exists no definition on how to define endoscopic remission using the SES-CD. 
We defined a semiquantitative SES-CD as follows:  
- inactive (remission)  0-3 
- mild activity             4-10 
- moderate activity   11-19 
- high activity             ≥20 points.  
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Fecal Calprotectin 
Fecal calprotectin was measured by a quantitative enzyme linked immunosorbent assay 
(PhiCalTM Test, purchased from Medical Instrument Corporation, Solothurn, Switzerland, Art-
No. 006, the test is delivered by CALPRO AS, Oslo, Norway). This sandwich ELISA 
measures quantitative calprotectin. Fecal specimens were diluted at 1:2500. The scientist 
(MT) performing the analyses was blinded to the patient names, the clinical and endoscopic 
findings. All fecal samples were processed within 72 hours after collection. The assays were 
performed according to the test instructions. ELISA plates were read on a Spectra mini 
reader (TECAN) at an OD of 450nm. According to the manufacturer, the calprotectin cutoff-
level representing a positive value was 50g calprotectin/g feces.  
 
CRP, and Blood Leukocytes 
Blood leukocytes (normal range 2.6-7.8 G/L), hemoglobin (normal range for women 120-
160g/L, for men 140-180g/L), a sedimentation rate (normal range for women and men up to 
50 years up to 20mm/h and 15mm/h, normal range for persons older than 50 years up to 
30mm/h and up to 20mm/h, respecitvely) as well as CRP (upper limit of normal <5mg/L) 
were determined as routine laboratory values within 3 days prior to endoscopy.  
 
Statistical Analysis 
Data were listed on an Excel sheet (Microsoft Excel 2003; Microsoft Switzerland Ltd Liab. 
Co., Wallisellen, Switzerland), statistical analyses were performed with a statistical package 
program (Stata Vs 9, College Station, Texas, USA). Results of numerical data are presented 
as mean  standard deviation (SD), and range. Normal distribution of data was tested using 
a Normal-QQ-Plot. Fisher’s exact test (two-sided) or the Chi squared test was used to 
explore associations of categorical data in 2 independent groups. The Wilcoxon rank sum 
test was used to explore associations of numerical data in 2 independent groups. A P < 0.05 
was considered statistically significant. A Bonferoni adjustment was performed in case of 
multiple testing. The association between endoscopic disease activity with CDAI, fecal 
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calprotectin, CRP, and blood leukocytes was assessed by determination of the Spearman’s 
rank correlation coefficient (r) for nonparametric correlations. The test characteristics are 
given as sensitivity, specificity, positive and negative predictive value (SENS, SPEC, PPV, 
NPV), and overall accuracy. The overall accuracy is calculated by addition of the true-
positive and true-negative test results divided by all tests (a+d)/(a+b+c+d) and admits the 
comparative evaluation of the various tests.  
A power analysis revealed that a sample size of 17 in each of the four subgroups of 
endoscopic disease activity (total n=68) would have 90% power to detect a difference in the 
mean calprotectin between the subgroups, using a Mann-Whitney rank-sum test with a 0.05 
two-sided significance level.  
  
RESULTS 
Patient and Controls Characteristics 
The clinical characteristics of the patients and healthy controls are shown in Table 1. 
Disease phenotypes were grouped according to the Montreal classification.24 As therapy 
regimens overlapped, the total counts for more than 100% (131%). The controls were 
healthy persons from the clinical and laboratory staff willing to provide blood and fecal 
samples.  
The baseline clinical as well as laboratory characteristics of CD patients and controls are 
demonstrated in Table 2. Calprotectin, CRP, and blood leukocytes were significantly higher 
in CD patients compared to controls (all P <0.001). 
 
Correlation of the SES-CD with CDAI, Fecal Calprotectin, CRP, and Blood Leukocytes 
The Endoscopic Activity Index correlated significantly with levels of fecal calprotectin 
(Spearman’s rank correlation coefficient r = 0.75), CRP (r = 0.53), blood leukocytes (r = 
0.42), and CDAI (r = 0.38). For all items a P < 0.01 was found. Figure 1 demonstrates the 
correlation between the SES-CD and fecal calprotectin with a scatter plot.  
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In Table 3, we present the relationship between the different subgroups of the SES-CD with 
their corresponding CDAI, fecal calprotectin, CRP, and blood leukocytes (values given as 
meanSD and range).  
Calprotectin was the only biomarker able to discriminate the four subgroups of SES-CD (P 
<0.001 for discriminating inactive from mild disease, P = 0.008 for discriminating mild from 
moderate, and P <0.001 for discriminating moderate from high endoscopic activity). This 
finding is further illustrated by Figure 2.  
The CDAI could neither discriminate inactive from mild nor mild from moderate endoscopic 
activity. The only significance in CDAI was found for discrimination of moderate versus highly 
active endoscopic disease (P <0.001). CRP was able to discriminate mild from moderate and 
moderate versus high endoscopic activity (P = 0.013 and P = 0.019), however, CRP failed to 
discriminate inactive from mildly active endoscopic disease. A difference in the blood 
leukocyte counts was detected only between moderate versus highly active endoscopic 
disease.  
 
Test Characteristics of CDAI, Fecal Calprotectin, CRP, and Blood Leukocytes in 
Predicting Endoscopically Active Disease  
The test performance (given by sensitivity/specificity/positive and negative predictive value in 
percent) of CDAI, fecal calprotectin with 2 cutoffs, CRP, and blood leukocytes in predicting 
endoscopically active disease (SES-CD   4) is demonstrated in Table 4.  
In summary, calprotectin with a cutoff of  50g/g had the best overall accuracy (84%) for the 
detection of endoscopically active disease, followed by elevated CRP (accuracy 66%), then 
blood leukocytosis (accuracy 54%), and finally CDAI 150 (accuracy 40%). Taking the higher 
cutoff of 100g/g calprotectin did not improve the overall accuracy (82% vs 84% with 50g/g 
as recommended by the manufacturer).  
 
DISCUSSION 
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This study demonstrates that fecal calprotectin correlates very closely with the endoscopic 
disease activity and was the only biomarker that could discriminate inactive from mild, 
moderate, and highly active disease. Second, the CDAI (cutoff ≥150) presented the worst 
overall accuracy for detection of endoscopically active disease.  
Several groups have already shown that fecal calprotectin is correlated to the endoscopic 
disease activity in pediatric and adult CD patients. However, studies assessing the 
correlation between a semiquantitatively captured endoscopic disease activity according the 
SES-CD and fecal calprotectin are scarce. Sipponen and coworkers evaluated the 
correlation of fecal calprotectin and lactoferrin with the SES-CD in a cohort of 61 CD patients 
(87 ileo-colonoscopies) and applied a semiquantitative assessment of endoscopic activity to 
a certain extent comparable to our classification (SES-CD: inactive 0-3, mild or moderate 4-
14, severe ≥15).20 They found that fecal calprotectin could discriminate inactive from mild to 
moderate and highly active endoscopic disease. Our results are in accordance with their 
findings regarding the good performance of fecal calprotectin to discriminate between 
different inflammatory activities. Comparable to our findings, the correlation between SES-
CD and calprotectin was closer than with CRP, blood leukocytes, and CDAI.  
Langhorst and coworkers evaluated in a cohort of 43 adult CD patients fecal calprotectin 
besides lactoferrin, PMN-elastase, CRP, and clinical indices.15 They calculated an 
endoscopic disease activity by means of a semiquantitative four-degree system (comparable 
to our arrangement with the SES-CD) and reported a significant correlation of calprotectin 
with the binary ordered (active vs. non-active) endoscopic disease activity. No correlation of 
calprotectin or any other fecal marker was reported with subclasses of endoscopic 
inflammatory activity. Comparable to our data, they documented significant correlations of 
SES-CD with fecal calprotectin, CRP, and CDAI. However, their SES-CD calprotectin 
correlation coefficient (r = 0.35) is lower than ours (r = 0.75) which is probably related to our 
larger patient cohort and our inclusion of a relatively high proportion of patients with high 
inflammatory activity. Canani and coworkers assessed in a pediatric cohort of 26 CD patients 
the correlation between fecal calprotectin, endoscopic activity, and mucosal inflammation 
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using a histopathologic score.11 Fecal calprotectin showed a good correlation with the 
histologic and endoscopic grade of colonic inflammation. Again, a correlation of calprotectin 
with the different degrees of endoscopic activity is not reported.  
Jones and coworkers evaluated in a cohort of 164 CD patients the relationship between 
endoscopic (measured by SES-CD) and clinical disease activity (CDAI) and serum (hsCRP, 
IL-6) and fecal bimoarkers (calprotectin and lactoferrin).25 In accordance to the above cited 
studies, they reported significant correlations of SES-CD with fecal and serum biomarkers. 
However, and this stands in contrast to the above cited reports, they found no correlation 
between SES-CD and CDAI.   
The question may arise if it is necessary at all to assess the extent of mucosal damage and if 
it is not sufficient to treat CD patients solely with the focus on clinical remission. First, CDAI 
has an insufficient ability to detect low-grade mucosal inflammation. We found that CDAI was 
not able to discriminate between inactive versus mild and mild versus moderate endoscopic 
activity; of note, the sensitivity of CDAI for detection of endoscopically active disease was 
only 33 percent. Similar findings were reported in the study of Sipponen and coworkers.20 
Thus, caution should be exercised when interpreting CDAI data in relation to endoscopic 
activity. Furthermore, certain items of the CDAI vary because of individual particularities such 
as a variable weekly stool frequency if irritable bowel symptoms are superimposed on CD 
activity. Such IBS like symptoms have been reported in two-to three times higher frequency 
in IBD patients in remission compared to the normal population.26 Second, anti-inflammatory 
therapy is associated with a reduction of CD-related hospitalizations and surgical 
procedures.27,28 Thereby, achievement of mucosal healing may alter the natural course of 
the disease. The established symptom-based therapeutic concept (by measuring CDAI) 
should therefore be reconsidered. Whether mucosal healing is definitely a therapeutic goal in 
the treatment of CD remains to be proven in further prospective studies evaluating disease 
outcome, but at least, the assessment of mucosal healing should be included in clinical trials 
as an important outcome variable. Since fecal calprotectin closely correlates with 
endoscopically assessed mucosal damage and since patient’s acceptance for fecal sampling 
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is high 29 this biomarker should be useful to monitor the extent of mucosal damage in 
Crohn’s disease.   
It should be kept in mind that fecal calprotectin is an unspecific biomarker and may be 
elevated in non-IBD related inflammations such as bacterial or drug-induced enterocolitis.30 
Endoscopy has an established role in CD assessment especially if the disease course 
deteriorates under therapy (search for CMV superinfection). However, when the patient 
improves under therapy and the extent of residual mucosal inflammation has to be assessed, 
non-invasive and cheap biomarkers such as fecal calprotectin seem preferable over 
logistically demanding endoscopic procedures.31 
Our results regarding the performance of elevated CRP to detect endoscopically active 
disease are comparable to an earlier publication of our group and compare also well to the 
results of Sipponen and coworkers.12,20 Polymorphisms in the CRP gene can be  
responsible for interindividual differences in CRP production in humans.32 Assessment of 
blood leukocytosis for detection of active endoscopic disease has obviously limitations. 
These may be explained by the fact that CD patients are usually under therapy with 
immunomodulators that can affect absolute leukocyte numbers.  
Our study has several potential limitations. The first may be our decision not to assess 
further fecal leukocyte markers besides calprotectin. We voted against inclusion of lactoferrin 
because we have assessed this marker in two recent studies and found the results to 
compare well with calprotectin.12,29 We further omitted the determination of PMN-elastase 
in feces because a well conducted trial again demonstrated similar results with calprotecctin 
and lactoferrin for detection of active endoscopic disease.15 Second, the topic of mucosal 
healing is controversially discussed and available data on the significance in Crohn’s disease 
are so far limited. Despite that, our results provide evidence that mucosal healing can non-
invasively be measured by calprotectin as surrogate marker. Third, an ileo-colonoscopy may 
not be sufficient to detect the whole extent of CD. In the absence of symptoms, we did not 
perform a systematic search for CD involvement of the upper gastrointestinal tract and small 
bowel because this would have represented an imbalance between diagnostic expenses on 
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the one and expected yield on the other hand. We tried to reduce the inevitable diagnostic 
blurring by offering upper endoscopies to CD patients with symptoms compatible of upper 
gastrointestinal tract CD involvement.  
In summary, we demonstrated that fecal calprotectin was the only marker that could reliably 
discriminate inactive from mild, moderate, and severe endoscopic activity. Therefore, fecal 
calprotectin has the potential to replace endoscopy in the disease monitoring of Crohn’s 
disease. Measuring CDAI is not appropriate for assessment of endoscopic inflammatory 
activity.  
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Tables 
 
Table 1.  Clinical characteristics of the CD patients’ cohort according the Montreal 
classification.  
Abbreviations: CD = Crohn’s disease. HC = healthy controls.  
Behaviour: B1 = non-stricturing, non-penetrating; B2 = stricturing, B3 = 
penetrating; p = perianal disease.  
Location: L1 = ileal; L2 = colonic, L3 = ileocolonic, L4 = isolated upper disease 
(L4 is added to L1-L3 when concomitant upper disease is present).  
 
  CD HC 
 Number of patients 122 43 
 Female  71 (58%) 32 (74%) 
 Age: meanSD, range 4216 (19-83) 3711 (25-61) 
 Mean disease duration (years) 13.26.1 - 
 Age at diagnosis - A1 (<16yrs)     13 (11%) 
- A2 (17-40yrs)  92 (75%) 
- A3 (≥40yrs)     17 (14%) 
- 
 Disease phenotype - B1:                  54 (44%) 
- B1p:                  7 (6%) 
- B2:                  31 (25%) 
- B2p:                  7 (6%) 
- B3:                  18 (15%) 
- B3p:                  5 (4%) 
- 
 Disease location - L1:                35 (29%) 
- L2:                20 (16%) 
- L3:                67 (55%) 
- 
 Prior CD related surgery 37 (30%) - 
 Smoking status  19 (16%) 16.5 
 Medication at endoscopy 
   No Medication 
   5-ASA 
   Corticosteroids 
   Azathioprine 
   6-Mercaptopurine 
   Methotrexate 
   TNF-alpha Inhibitor 
 
8  (7%) 
6  (5%) 
19  (16%) 
73  (60%) 
18  (15%) 
14  (11%) 
21  (17%) 
 
- 
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Table 2.  Baseline clinical and laboratory characteristics of CD patients and healthy 
controls. Calprotectin, CRP, and blood leukocytes were significantly higher in 
CD patients compared to controls (all P <0.001).  
 Abbreviations: SD = standard deviation; CI = confidence interval; HC = healthy 
controls; SES-CD = simple endoscopic score for Crohn’s disease; CDAI = 
Crohn’s disease activity index; CRP = C-reactive protein.  
 
 CD patients Controls 
Parameter MeanSD 95%-CI Range MeanSD 95%-CI Range 
SES-CD 1413 0-45 0-46 - - - 
CDAI 16099 12-402 -13-417 - - - 
Calprotectin (g/g) 334322 15-1083 10-1327 185 11-26 10-34 
CRP (mg/L) 2629 3-121 3-172 32 2-8 2-17 
Leukocytes (G/L) 9.13.4 2.9-17.8 1.5-18.8 5.41.9 3.6-8.1 3.5-12.4
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Table 3. Correlation of the Simple Endoscopic Score for Crohn’s Disease (SES-CD) 
subgroups with fecal calprotectin, CRP, CDAI, and blook leukocytes.  
 Numbers are presented as meanSD and range. The corresponding P-values 
for discrimination between the different subgroups are listed in grey.  
Abbreviations: NS = not significant. CDAI: Crohn’s Disease Activity Index 
  
 
Endoscopic 
Activity  
Inactive (0-3) Mild (4-10) Moderate (11-19) High (≥20) 
No of patients 26 40 27 47 
CDAI 7986 (-13-281) 8570 (14-297) 11647 (44-323) 21875 (86-417) 
    P-Value 0.739 0.201 <0.001 
Calprotectin g/g 104138 (10-725) 231244 (12-1009) 395256 (68-912) 718320 (93-1327) 
    P-Value <0.001 0.008 <0.001 
CRP mg/L 1219 (3-94) 810 (3-53) 2331 (3-172) 4028 (5-121) 
    P-Value 0.349 0.013 0.019 
Leukocytes G/L 7.73.1 (4-17.9) 7.62.8 (3.7-13.6) 8.83.1 (1.4-15.8) 11.13.5 (2.9-18.6) 
    P-Value 0.903 0.117 0.004 
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Table 4.   Sensitivity (SENS), Specificity (SPEC), Positive (PPV), Negative Predictive 
Value (NPV), and the overall Accuracy of fecal calprotectin, CRP, CDAI  150, 
and blood leukocytes in predicting endoscopically active disease (SES-CD 
4).  
 
 
 SENS (%) SPEC (%) PPV (%) NPV (%) Accuracy (%)
Calprotectin  50g/g 89 59 89 61 84 
Calprotectin  100g/g 84 74 83 77 82 
CRP  5mg/L 68 58 88 29 66 
Blood Leukocytes  7.9G/L 55 50 83 21 54 
CDAI  150 33 68 80 20 40 
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Figures 
Figure 1 Correlation of the SES-CD with fecal calprotectin 
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Figure 2  Correlation between SES-CD activity and fecal calprotectin.  
  Abbreviations: SES-CD = Simple Endoscopic Score for Crohn’s Disease 
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